Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

‘Open to Options’ guides cancer patients in making critical health decisions

‘Open to Options’ guides cancer patients in making critical health decisions

Connections between daily stressors of police work and obesity, suicide

Connections between daily stressors of police work and obesity, suicide

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Blocking a fundamental process deep within cancer cells can selectively kill them

Blocking a fundamental process deep within cancer cells can selectively kill them

Novel treatment for cancer based on protein from HIV-1 virus

Novel treatment for cancer based on protein from HIV-1 virus

Conference highlights utility of zebrafish for human disorder studies

Conference highlights utility of zebrafish for human disorder studies

Cystic fibrosis patient receives generous 'gift of life'

Cystic fibrosis patient receives generous 'gift of life'

ADCT, CRT sign agreements to develop ADCs against cancer

ADCT, CRT sign agreements to develop ADCs against cancer

Scientists identify causative link between oncometabolite and onset of AML

Scientists identify causative link between oncometabolite and onset of AML

Researchers identify new gene target for leukemia therapy

Researchers identify new gene target for leukemia therapy

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

CHLA pediatric oncologist receives Hyundai Hope on Wheels grant

CHLA pediatric oncologist receives Hyundai Hope on Wheels grant

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Experimental medication increases muscle strength in cancer patients with low testosterone levels

Experimental medication increases muscle strength in cancer patients with low testosterone levels

GMCSF linked with rapid cognitive recovery in patients with cancer

GMCSF linked with rapid cognitive recovery in patients with cancer

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

A potential drug target for NK/T-cell lymphoma

A potential drug target for NK/T-cell lymphoma

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.